Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_219_библиотеки_им_акад_М_И_Перельмана
.pdf
221
65. Chronic kidney disease and arrhythmias: conclusions from a Kidney Dis-
ease: Improving Global Outcomes (KDIGO) Controversies Conference / M.P. Turakhia,
P.J. Blankestijn, J.J. Carrero [et al.] // European Heart Journal. – 2018. – Vol.39, №24. –
P. 2314-2325.
66. Cleary, F. A systematic review of statistical methodology used to evaluate
progression of chronic kidney disease using electronic healthcare records [Электронный
ресурс] / F. Cleary // PLoS One. – 2022. – Vol.17, №7. – e0264167. - Режим доступа:
https://pubmed.ncbi.nlm.nih.gov/35905096/
67. CKD-EPI Equations for Glomerular Filtration Rate (GFR) [Электронный
ресурс]/ Режим доступа: https://www.mdcalc.com/calc/3939/ckd-epi-equations-glo-
merular-filtration-rate-gfr
68. Clinical frailty assessment might be associated with mortality in incident di-
alysis patients [Электронный ресурс] / R. Oki, Y. Hamasaki, S. Tsuji. [et al.] // Scientific
Reports. – 2022. – Vol.12, №1. – P. 17651. – Режим доступа: https://www.na-
ture.com/articles/s41598-022-22483-8
69. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibi-
tors in Treating Nonanemic Diseases [Электронный ресурс] / M. Miao, M. Wu, Y. Li
[et al.] // Frontiers in Pharmacology. – 2022. – Vol.13. – P. 837249. Режим доступа:
https://pubmed.ncbi.nlm.nih.gov/35281917/
70. Clinical Trial Considerations in Developing Treatments for Early Stages of
Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National
Kidney Foundation and the US Food and Drug Administration / L.A. Inker, M.E. Grams,
H. Guðmundsdóttir [et al.] // American Journal of Kidney Diseases. – 2022. – Vol.80,
№4. – P. 513-526.
71. Cohen, J.B. Obesity, Renin-Angiotensin System Blockade and Risk of Ad-
verse Renal Outcomes: A Population-Based Cohort Study / J.B. Cohen, A.J. Stephens-
Shields, M.R. Denburg [et al.] // American Journal of Nephrology. – 2016. – Vol.43, №6.
– P. 431-40.
72. Comorbidity burden at dialysis initiation and mortality: A cohort study
[Электронный ресурс] / A.T. Gomez, B.A. Kiberd, J.P. Royston [et al.] // Canadian
https://t.me/med1917
222
Journal of Kidney Health and Disease. – 2015. – Vol.2. – P. 34. – Режим доступа:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562341/
73. Comorbidity is not associated with dialysis modality choice in patients with
end-stage kidney disease / A.A. Bonenkamp, S. Vonk, A.C. Abrahams [et al.] // Nephrol-
ogy (Carlton). – 2022. – Vol.27, №6. – P. 510-518.
74. Comparative effectiveness of allopurinol and febuxostat in gout manage-
ment [Электронный ресурс] / J.R. O’Dell, M.T. Brophy, M.H. Pillinger [et al.] // NEJM
Evidence. – 2022. – Vol.1, №3. – P. 10. – Режим доступа: https://evi-
dence.nejm.org/doi/full/10.1056/EVIDoa2100028
75. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Cal-
cium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observa-
tional Cohort Study / E.L. Fu, C.M. Clase, M. Evans [et al.] // American Journal of Kidney
Diseases. – 2021. – Vol.77, №5. – P. 719-729.
76. Comparison of annual eGFR decline among primary kidney diseases in pa-
tients with CKD G3b-5: results from a REACH-J CKD cohort study / J. Hoshino, R.
Tsunoda, K. Nagai [et al.] // Clinical and Experimental Nephrology. – 2021. – Vol.25,
№8. – P. 902-910.
77. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Ran-
domized, Controlled Trial / T. Hayashi, S. Maruyama, M. Nangaku [et al.] // Clinical
Journal of the American Society of Nephrology. – 2020. – Vol.15, №5. – P. 608-615.
78. Dasgupta, I. Is the KDIGO Systolic Blood Pressure Target <120 mm Hg for
Chronic Kidney Disease Appropriate in Routine Clinical Practice? / I. Dasgupta, C.
Zoccali // Hypertension. – 2022. – Vol.79, №1. – P. 4-11.
79. Decline of kidney function during the pre-dialysis period in chronic kidney
disease patients: a systematic review and meta-analysis / C.J. Janmaat, M. van Diepen,
C.C. van Hagen [et al.] // Clinical Epidemiology. – 2018. – Vol.10. – P. 613-622.
80. Delaying initiation of dialysis till symptomatic uraemia - is it too late? / S.C.
Tang, Y.W. Ho, A.W. Tang [et al.] // Nephrology Dialysis Transplantation. – 2007. –
Vol.22, №7. – P. 1926-1932.
https://t.me/med1917
223
81. Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk
and Kidney Function Loss in Chronic Kidney Disease (CKD) [Электронный ресурс] /
R. Vanholder, S. Van Laecke, G. Glorieux [et al.] // Toxins. – 2018. – Vol.10, №6. – P.
237. – Режим доступа: https://repositorio.uam.es/bitstream/handle/10486/685156/delet-
ing_vanholder_toxins_2018.pdf?sequence=1&isAllowed=y
82. Detrimental effect of renin-angiotensin blockade on progression of chronic
kidney disease at later stages: A matter of dosage adjustment? / F. Caravaca-Fontán, J.
Valladares, R. Díaz-Campillejo [et al.] // Nefrología (English Edition) | Journal. – 2020.
– Vol.40, №1. – P. 38-45.
83. Development and Validation of a Modified Full Age Spectrum Creatinine-
Based Equation to Estimate Glomerular Filtration Rate: A Cross-sectional Analysis of
Pooled Data / H. Pottel, J. Björk, M. Courbebaisse [et al.] // Annals of Internal Medicine.
– 2021. – Vol.174, №2. – P. 183-191.
84. Diabetes Management in Chronic Kidney Disease: A Consensus Report by
the American Diabetes Association (ADA) and Kidney Disease: Improving Global Out-
comes (KDIGO) / I.H. de Boer, K. Khunti, T. Sadusky [et al.] // Diabetes Care. – 2022.
– Vol.45, №12. – P. 3075-3090.
85. Diagnosis and Prediction of CKD Progression by Assessment of Urinary
Peptides / J.P. Schanstra, P. Zürbig, A. Alkhalaf [et al.] // Journal of the American Society
of Nephrology. – 2015. – Vol.26, №8. – P. 1999-2010.
86. Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: a sys-
tematic review and meta-analysis / X. Shu, T. Lin, H. Wang [et al.] // Journal of Cachexia,
Sarcopenia and Muscle. – 2022. – Vol.13, №1. – P. 145-158.
87. Dialysis initiation, modality choice, access, and prescription: conclusions
from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Confer-
ence / C.T. Chan, P.J. Blankestijn, L.M. Dember [et al.] // Kidney International. – 2019.
– Vol.96, №1. – P. 37-47.
88. Dialysis timing may be deferred toward very late initiation: An observational
study [Электронный ресурс] / Y.L. Chang, J.S. Wang, H.C. Yeh [et al.] // PLoS One. –
https://t.me/med1917
224
2020. – Vol.15, №5. – P. e0233124. – Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/32401817/
89. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid
Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
/ S.C. Goulooze, H.J.L. Heerspink, M. van Noort [et al.] // Clinical Pharmacokinetics. –
2022. – Vol.61, №7. – P. 1013-1025.
90. Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle
weakness and atrophy similarly influence poor outcome? / J.S. Souweine, G. Pasquier,
N. Kuster [et al.] // Nephrology Dialysis Transplantation. – 2021. – Vol.36, №10. – P.
1908-1918.
91. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA
Nephropathy: An Individual-Patient Meta-analysis / L.A. Inker, H. Mondal, T. Greene
[et al.] // American Journal of Kidney Diseases. – 2016. – Vol.68, №3. – P. 392-401.
92. Early low-dose erythropoiesis-stimulating agent therapy and progression of
moderate chronic kidney disease: a randomized, placebo-controlled trial / D. Fliser, F.
Dellanna, M. Koch, A. Wiggenhauser // Nephrology Dialysis Transplantation. – 2017. –
Vol.32, №2. – P. 279-287.
93. Early Referral to Nephrological Care and the Uptake of Peritoneal Dialysis.
An Analysis of German Cl aims Data [Электронный ресурс] / I. Schellartz, S. Mettang,
A. Shukri [et al.] // International Journal of Environmental Research and Public Health.
– 2021. – Vol.18, №16. – P. 8359. – Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/34444109/
94. Early referral to specialist nephrology services for preventing the progres-
sion to end-stage kidney disease [Электронный ресурс]/ N.A. Smart, G. Dieberg, M.
Ladhani, T. Titus // The Cochrane database of systematic reviews. – 2014. – Vol., №6. –
P. CD007333. - Режим доступа: https://pubmed.ncbi.nlm.nih.gov/24938824/
95. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal
Disease and Death Among Subgroups of Patients With Chronic Kidney Disease
[Электронный ресурс] / E. Ku, M.J. Sarnak, R. Toto [et al.] // Journal of the American
https://t.me/med1917
225
Heart Association. – 2019. – Vol.8, №16. – P. e012749. – Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/31411082/
96. Effect of dapagliflozin on the rate of decline in kidney function in patients
with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from
the DAPA-CKD trial. Lancet Diabetes Endocrinol / H.J.L. Heerspink, N. Jongs, G.M.
Chertow [et al.] // 2021. – Vol.9, №11. – P. 743-754.
97. Effect of emergency start and central venous catheter on outcomes in inci-
dent hemodialysis patients: a prospective observational cohort / U. Alizada, E.A. Sauleau,
T. Krummel [et al.] // Journal of Nephrology. – 2022. – Vol.35, №3. – P. 977-988.
98. Effect of hemoglobin target on progression of kidney disease: a secondary
analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency)
trial / J.K. Inrig, H.X. Barnhart, D. Reddan [et al.] // American Journal of Kidney Dis-
eases. – 2012. – Vol.60, №3. – P. 390-401.
99. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression:
The SURE-PD3 Randomized Clinical Trial / M.A. Schwarzschild, A. Ascherio, C. Ca-
saceli [et al.] // JAMA. – 2021. – Vol.326, №10. – P. 926-939.
100. Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs
and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in
adults: a systematic review and meta-analysis / K.S. Taylor, J. Mclellan, J.Y. Verbakel
[et al.] // BMJ Open. – 2019. – Vol.9, №9. – P. e030596.
101. Effects of arteriovenous fistula formation on arterial stiffness and cardiovas-
cular performance and function / S. Korsheed, M.T. Eldehni, S.G. John [et al.] // Neph-
rology Dialysis Transplantation. – 2011. – Vol.26, №10. – P. 3296-3302.
102. Effects of dapagliflozin on development and progression of kidney disease
in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised
trial / O. Mosenzon, S.D. Wiviott, A. Cahn [et al.] // The Lancet Diabetes & Endocrinol-
ogy. – 2019. – Vol.7, №8. – P. 606-617.
103. Effects of dapagliflozin on major adverse kidney and cardiovascular events
in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis
https://t.me/med1917
226
from the DAPA-CKD trial / D.C. Wheeler, B.V. Stefánsson, .N Jongs [et al.] // The Lan-
cet Diabetes & Endocrinology. – 2021. – Vol.9, №1. – P. 22-31.
104. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in pa-
tients with type 2 diabetes and established cardiovascular disease: an exploratory analysis
from the EMPA-REG OUTCOME randomised, placebo-controlled trial / D.Z.I. Cherney,
B. Zinman, S.E. Inzucchi [et al.] // The Lancet Diabetes & Endocrinology. – 2017. –
Vol.5, №8. – P. 610–621.
105. Effects of exercise on kidney and physical function in patients with non-di-
alysis chronic kidney disease: a systematic review and 29-analysis / K. Nakamura, T.
Sasaki, S. Yamamoto [et al.] // Scientific Reports. – 2020. – Vol.10, №1. – P. 18195.
106. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review
and Meta-Analysis / S.D. Navaneethan, J. Shao, J. Buysse, D.A. Bushinsky // Clinical
Journal of the American Society of Nephrology. – 2019. – Vol.14, №7. – P. 1011-1020.
107. Elevated levels of serum creatinine: recommendations for management and
referral / D.C. Mendelssohn, B.J. Barrett, L.M. Brownscombe [et al.] // CMAJ : Canadian
Medical Association journal. – 1999. – Vol.161, №4. – P. 413-417.
108. Emergent initiation of dialysis is related to an increase in both mortality and
medical costs [Электронный ресурс] / Y. Shimizu, J. Nakata, N. Yanagisawa [et al.] //
Scientific Reports. – 2020. – Vol.10, №1. – P. 19638. Режим доступа: https://www.na-
ture.com/articles/s41598-020-76765-0
109. Emerging Treatments for Insomnia, Sleep Apnea, and Restless Leg Syn-
drome Among Dialysis Patients / S. Diaz, K. Abad, S.R. Patel, M.L. Unruh // Seminars
in Nephrology. – 2021. – Vol.41, №6. – P. 526-533.
110. EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline
characteristics of the EMPA-KIDNEY trial / Nephrology Dialysis Transplantation. –
2022. – Vol.37, №7. – P. 1317-1329.
111. EMPA-KIDNEY Collaborative Group: Empagliflozin in Patients with
Chronic Kidney Disease / The New England Journal of Medicine. – 2023. – Vol.388, №2.
– P. 117-127.
https://t.me/med1917
227
112. Epidemiology of haemodialysis outcomes / A.K. Bello, I.G. Okpechi, M.A.
Osman [et al.] // Nature Reviews Nephrology. – 2022. – Vol.18, №6. – P. 378-395.
113. Estimated Glomerular Filtration Rate in Chronic Kidney Disease: A Critical
Review of Estimate-Based Predictions of Individual Outcomes in Kidney Disease
[Электронный ресурс] / L. Zsom, M. Zsom, S.A. Salim, T. Fülöp // Toxins. – 2022. –
Vol.14, №2. – P. 127. Режим доступа: https://pubmed.ncbi.nlm.nih.gov/35202154/
114. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration
equation for estimating the glomerular filtration rate in multiple ethnicities / L.A. Stevens,
M.A. Claybon, C.H. Schmid [et al.] // Kidney International. – 2011. – Vol.79, №5. – P.
555-562.
115. Factors affecting pre-end-stage kidney disease haemoglobin control and out-
comes following dialysis initiation: a nationwide study / Y. Xu, M. Evans, P. Barany [et
al.] // Clinical Kidney Journal. – 2021. – Vol.14, №7. – P. 1780-1788.
116. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney
Disease and Type 2 Diabetes / G. Filippatos, S.D. Anker, R. Agarwal [et al.] // Circula-
tion. – 2021. – Vol.143, №6. – P. 540-552.
117. Five-year Estimated Glomerular Filtration Rate in Patients With Hypopara-
thyroidism Treated With and Without rhPTH, №1-84) / K.S. Chen, E.O. Gosmanova,
G.C. Curhan [et al.] // The Journal of Clinical Endocrinology & Metabolism. – 2020. –
Vol.105, №10. – P. e3557–е3565.
118. Franco, R.P. Is the Fistula First Approach still valid? / R.P. Franco // Brazil-
ian Journal of Nephrology. – 2021. – Vol.43, №2. – P. 263-268.
119. Genovesi, S. Sudden cardiac death in dialysis patients: different causes and
management strategies / S. Genovesi, G. Boriani, A. Covic // Nephrology Dialysis Trans-
plantation. – 2021. – Vol.36, №3. – P. 396-405.
120. Georgianos, P.I. Effect of angiotensin converting enzyme inhibitors or angi-
otensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic
review and meta-analysis / P.I. Georgianos, G. Tziatzios, S. Roumeliotis [et al.] // Neph-
rology Dialysis Transplantation. – 2023. – Vol.38, №1. – P. 203-211.
https://t.me/med1917
228
121. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clin-
ical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials / L.A.
Inker, H.J.L. Heerspink, H. Tighiouart [et al.] // Journal of the American Society of Neph-
rology. – 2019. – Vol.30, №9. – P. 1735-1745.
122. Goh, ZS. Anxiety and depression in patients with end-stage renal disease:
impact and management challenges – a narrative review / Z.S. Goh, K. Griva // Int J
Nephrol Renovasc Dis. – 2018. – Vol.11. – P. 93-102
123. Hahn, D. Low protein diets for non-diabetic adults with chronic kidney dis-
ease [Электронный ресурс] / D. Hahn, E.M. Hodson, D. Fouque // Cochrane Database
of Systematic Reviews. – 2020. – Vol.10, №10. – P. CD001892. – Режиим доступа:
https://pubmed.ncbi.nlm.nih.gov/30284724/
124. Heyman, S.N. Diabetic Proteinuria Revisited: Updated Physiologic Perspec-
tives [Электронный ресурс]/ S.N. Heyman // Cells. – 2022. – Vol.11, №18. – P. 2917.
– Режиим доступа: https://pubmed.ncbi.nlm.nih.gov/36139492/
125. Hypoglycemia-Related Hospitalizations and Mortality Among Patients With
Diabetes Transitioning to Dialysis / C.M. Rhee, C.P. Kovesdy, A.S. You [et al.] // Amer-
ican Journal of Kidney Diseases. – 2018. – Vol.72, №5. – P. 701-710.
126. Identifying subgroups of renal function trajectories / J. Boucquemont, L.
Loubère, M. Metzger [et al.] // Nephrology Dialysis Transplantation. – 2017. – Vol. 32,
Suppl. 2. – P. ii185-ii193.
127. Immune cells and inflammation in AKI to CKD progression / Y. Sato, M.
Yanagita // American Physiological Society Journal. – 2018. – Vol.315. – P. F1501–
F1512.
128. Impact of Arteriovenous fistula creation on estimated glomerular filtration
rate decline in Predialysis patients [Электронный ресурс] / V. Bénard, M. Pichette, J.P.
Lafrance [et al.] // BMC Nephrology. – 2019. – Vol.20, №1. – P. 420. – Режиим доступа:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876290/
129. Implication of Trends in Timing of Dialysis Initiation for Incidence of End-
stage Kidney Disease / C.Y. Hsu, R.V. Parikh, L.N. Pravoverov [et al.] // JAMA Interna-
tional Medicine. – 2020. – Vol.180, №12. – P. 1647-1654.
https://t.me/med1917
229
130. Improving Incident ESRD Care Via a Transitional Care Unit / B. Bowman,
S. Zheng, A. Yang [et al.] // Am J Kidney Dis. – 2018. – Vol.72, №2. – P. 278-283.
131. Improving Outcomes in Patients Receiving Dialysis: The Peer Kidney Care
Initiative / J.B. Wetmore, D.T. Gilbertson, J. Liu, A.J. Collins // Clinical Journal of the
American Society of Nephrology. – 2016. – Vol.11, №7. – P. 1297-304.
132. Improving the prognosis of patients with severely decreased glomerular fil-
tration rate (CKD G4+. – P. conclusions from a Kidney Disease: Improving Global Out-
comes (KDIGO) Controversies Conference / K.-U. Eckardt, N. Bansal, J. Coresh [et al.]
// Kidney International. – 2018. – Vol.93, №6. – P. 1281-1292.
133. Incremental dialysis in ESRD: systematic review and meta-analysis / C.
Garofalo, S. Borrelli, T. De Stefano [et al.] // Journal of Nephrology. – 2019. – Vol.32,
№5. – P. 823-836.
134. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant
polycystic kidney disease / T. Akihisa, H. Kataoka, S. Makabe [et al.] // Clin Exp Nephrol.
– 2022. – Vol.26, №6. – P. 540-551.
135. Inker, L.A. Evaluation of Surrogate End Points for Progression to ESKD:
Necessary and Challenging / L.A. Inker, H.L. Heerspink // American Journal of Kidney
Diseases. – 2018. – Vol.72, №6. – P. 771-773.
136. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renopro-
tective Drug Effects? / M. Weldegiorgis, D. de Zeeuw, J.P. Dwyer [et al.] // Clinical Jour-
nal of the American Society of Nephrology. – 2017. – Vol.12, №10. – P. 1595-1600.
137. Isaka, Y. Optimal Protein Intake in Pre-Dialysis Chronic Kidney Disease
Patients with Sarcopenia: An Overview [Электронный ресурс] / Y. Isaka // Nutrients. –
2021. – Vol.13, №4. – P. 1205. – Режим доступа: https://pub-
med.ncbi.nlm.nih.gov/33917381/
138. Joshi, S. Plant-Based Diets for Kidney Disease: A Guide for Clinicians / S.
Joshi, M. McMacken, K. Kalantar-Zadeh // American Journal of Kidney Diseases. –
2021. – Vol.77, №2. – P. 287-296.
https://t.me/med1917
230
139. Kaiser, P. A Virtual Multidisciplinary Care Program for Management of Ad-
vanced Chronic Kidney Disease: Matched Cohort Study [Электронный ресурс] / P. Kai-
ser, O. Pipitone, A. Franklin // Journal of Medical Internet Research. – 2020. – Vol.22,
№2. – P. e17194. – Режим доступа: https://pubmed.ncbi.nlm.nih.gov/32049061/
140. KDIGO Controversies Conference on Improving CKD Quality of Care:
Trends and Perspectives. 23-26.06.2022. [Электронный ресурс] / Режим доступа:
https://kdigo.org/conferences/ckd-quality-of-care/ доступ 31.01.23
141. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure
Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood
Pressure in Chronic Kidney Disease / Kidney International. – 2021. – Vol.99, №3S. – P.
S1-S87.
142. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Dis-
eases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glo-
merular Diseases / Kidney International. – 2021. – Vol.100, №4S. – P. S1-S276.
143. Kidney Failure Risk Equation (4 Variable) [Электронный ресурс]/ Режим
доступа: https://qxmd.com/calculate/calculator_308/kidney-failure-risk-equation-4-var-
iable
144. Kidney Failure Risk Equation (8 Variable) [Электронный ресурс]/ Режим
доступа: https://qxmd.com/calculate/calculator_125/kidney-failure-risk-equation-8-var-
iable
145. Ku, E. Association between strict blood pressure control during chronic kid-
ney disease and lower mortality after onset of end-stage renal disease / E. Ku, D.V. Glid-
den, K.L. Johansen // International. – 2015. – Vol.87, №5. – P. 1055-1060.
146. Lack or insufficient predialysis nephrology care worsens the outcomes in
dialyzed patients - call for action / A. Milkowski, T. Prystacki, W. Marcinkowski [et al.]
// Renal Failure. – 2022. – Vol.44, №1. – P. 946-957.
147. Late acceleration of glomerular filtration rate decline is a risk for hemodial-
ysis catheter use in patients with established nephrology chronic kidney disease care /
A.I. Chin, T.A. Nguyen, K.P. Dinesh, J.A. Morfin // Hemodialysis International. – 2015.
– Vol.19, №3. – P. 379-85.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана